Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 6/20 | 0.81 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 0.81 |
| ▸ | AVPR1B known ✓ | P47901 | 4/20 | 0.81 |
| ▸ | OXTR | P30559 | 9/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmopressin SCHEMBL347838 | 1.00 | OXTR (0.81) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL28142694 | 1.00 | OXTR (0.81) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL204511 | 0.99 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL6021294 | 0.99 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29354819 | 0.99 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| SCHEMBL23382246 | 0.98 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL15933169 | 0.98 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL2687079 | 0.98 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL21131126 | 0.98 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL10053268 | 0.98 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3513782-A1 | GEL FORMULATIONS FOR ORAL ADMINISTRATION OF DRUGS, IN PARTICULAR TO DYSPHAGIC PATIENTS | Universita' Degli Studi Di Camerino (IT) | 2019-07-24 | — | — | EP | claimed |
| EP-1121935-B1 | Pharmaceutical composition containing a small or medium size peptide | PATENTS EXPL COMPANY B V (NL) | 2008-08-13 | — | — | EP | claimed |
| US-6949509-B2 | Pharmaceutical composition containing a small or medium size peptide | PATENTS EXPLOITATION COMPANY B.V. (NL) | 2005-09-27 | — | — | US | claimed |
| US-20010027177-A1 | Pharmaceutical composition containing a small or medium size peptide | PEC INTELLECTUAL PROPERTY MANAGEMENT B.V. (NL) | 2001-10-04 | — | — | US | claimed |
| EP-1121935-A1 | Pharmaceutical composition containing a small or medium size peptide | Patents Exploitation Company B.V. (NL) | 2001-08-08 | — | — | EP | claimed |
| EP-4709350-A1 | INCREASING PERMEATION FOR PRE-GASTRIC ABSORPTION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Catalent U.K. Swindon Zydis Limited (GB) | 2026-03-18 | — | — | EP | disclosed |
| EP-3266389-B1 | VASCULAR EMBOLIZATION TOOL AND PRODUCTION METHOD THEREFOR | KANEKA MEDIX CORP (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20240374524-A1 | INCREASING PERMEATION FOR PRE-GASTRIC ABSORPTION OF ACTIVE PHARMACEUTICAL INGREDIENTS | CATALENT U.K. SWINDON ZYDIS LIMITED (GB) | 2024-11-14 | — | — | US | disclosed |
| WO-2024231554-A1 | INCREASING PERMEATION FOR PRE-GASTRIC ABSORPTION OF ACTIVE PHARMACEUTICAL INGREDIENTS | CATALENT U.K. SWINDON ZYDIS LIMITED (GB) | 2024-11-14 | — | — | WO | disclosed |
| US-20240316205-A1 | COMPOSITION CONTAINING CATIONIC HYDROXYETHYL CELLULOSE | NUTRITION & BIOSCIENCES USA 1 LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240074968-A1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | SUNSHO PHARMACEUTICAL CO LTD (JP) | 2024-03-07 | — | — | US | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| CN-105358133-A | Composition for application to a mucosa comprising a hydroxyalkyl methylcellulose | DOW GLOBAL TECHNOLOGIES LLC | 2016-02-24 | — | — | CN | disclosed |
| WO-2015047762-A1 | COMPOSITION FOR APPLICATION TO A MUCOSA COMPRISING A CELLULOSE ETHER | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015009796-A1 | COMPOSITION FOR APPLICATION TO A MUCOSA COMPRISING A METHYLCELLULOSE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015009799-A1 | COMPOSITION FOR APPLICATION TO A MUCOSA COMPRISING A HYDROXYALKYL METHYLCELLULOSE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-01-22 | — | — | WO | disclosed |
| EP-1121935-B1 | Pharmaceutical composition containing a small or medium size peptide | PATENTS EXPL COMPANY B V (NL) | 2008-08-13 | — | — | EP | disclosed |
| US-6949509-B2 | Pharmaceutical composition containing a small or medium size peptide | PATENTS EXPLOITATION COMPANY B.V. (NL) | 2005-09-27 | — | — | US | disclosed |
| US-20010027177-A1 | Pharmaceutical composition containing a small or medium size peptide | PEC INTELLECTUAL PROPERTY MANAGEMENT B.V. (NL) | 2001-10-04 | — | — | US | disclosed |
| EP-1121935-A1 | Pharmaceutical composition containing a small or medium size peptide | Patents Exploitation Company B.V. (NL) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316205-A1 | COMPOSITION CONTAINING CATIONIC HYDROXYETHYL CELLULOSE | SI, SLC10A2, VIP | AVPR1A 1142/4885AVPR2 941/4885AVPR1B 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.